International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.
Please fill out required fields.